Jagsonpal Pharmaceuticals Ltd Financials

Jagsonpal Pharmaceuticals Ltd Financial Statement

Jagsonpal Pharmaceuticals Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars	Mar 2025	Dec 2024	Sep 2024
Revenue	61.33	99.53	76.35
Operating Expense	50.06	58.19	58.41
Net Profit	6.58	31.99	11.46
Net Profit Margin	10.73	32.14	15.01
Earning Per Share	0.98	4.74	4.29
EBIDTA	10.39	42.72	16.71
Effective Tax Rate	11.00	19.50	14.94

Particulars	Mar 2025
Revenue	61.33
Operating Expense	50.06
Net Profit	6.58
Net Profit Margin	10.73
Earning Per Share	0.98
EBIDTA	10.39
Effective Tax Rate	11.00

Jagsonpal Pharmaceuticals Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Total Revenue Annual	208.70	236.71	217.58
Operating Expenses Annual	185.64	202.56	192.56
Operating Profit Annual	32.35	36.43	28.45
Interest Annual	0.81	0.41	0.29
Depreciation	1.66	1.18	1.53
Net Profit Annual	22.46	26.72	18.86
Tax Annual	7.41	8.09	7.79

Particulars	Mar 2024
Total Revenue Annual	208.70
Operating Expenses Annual	185.64
Operating Profit Annual	32.35
Interest Annual	0.81
Depreciation	1.66
Net Profit Annual	22.46
Tax Annual	7.41

Jagsonpal Pharmaceuticals Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Cash Flow at the Beginning	11.05	22.53	58.94
Cash Flow from Operations	35.17	46.66	6.91
Cash Flow from Investing	-24.55	-57.67	-25.78
Cash Flow from Financing	-8.91	-0.46	-17.55
Cash Flow at the End	12.76	11.05	22.53

Particulars	Mar 2024
Cash Flow at the Beginning	11.05
Cash Flow from Operations	35.17
Cash Flow from Investing	-24.55
Cash Flow from Financing	-8.91
Cash Flow at the End	12.76

Jagsonpal Pharmaceuticals Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
PBDIT Margin (%)	15.50	15.39	13.08
PBIT Margin (%)	14.70	14.87	12.38
PBT Margin (%)	-3.45	-21.42	-30.32
Net PROFIT Margin (%)	10.76	11.29	8.67
Return On Networth / Equity (%)	12.97	18.32	15.28
Return On Networth /Employed (%)	16.89	23.48	21.14
Return On Assets (%)	12.38	17.84	14.39
Total Debt / Equity (X)	0.04	0.02	0.03
Asset Turnover Ratio (%)	1.15	1.58	1.66

Particulars	Mar 2024
PBDIT Margin (%)	15.50
PBIT Margin (%)	14.70
PBT Margin (%)	-3.45
Net PROFIT Margin (%)	10.76
Return On Networth / Equity (%)	12.97
Return On Networth /Employed (%)	16.89
Return On Assets (%)	12.38
Total Debt / Equity (X)	0.04
Asset Turnover Ratio (%)	1.15

Jagsonpal Pharmaceuticals Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Fixed Assets Annual	9.30	24.28	22.60
Total Current Assets Annual	199.25	164.56	109.08
Non Current Assets Annual	17.82	30.39	55.14
Total Shareholders Funds Annual	187.40	158.89	132.76
Total Assets Annual	217.08	194.95	164.23

Particulars	Mar 2024
Fixed Assets Annual	9.30
Total Current Assets Annual	199.25
Non Current Assets Annual	17.82
Total Shareholders Funds Annual	187.40
Total Assets Annual	217.08

Jagsonpal Pharmaceuticals Ltd Earning Calls

No Data Availabe

Dividend Pages

PE Ratio

FAQS on Jagsonpal Pharmaceuticals Ltd Financials

As of May 9, 2025, Jagsonpal Pharmaceuticals Ltd has a market capitalization of 1,433.63 Cr. Value Research classifies it as a Small-Cap company.

Yes, Jagsonpal Pharmaceuticals Ltd is debt-free with a debt-to-equity ratio of 0.04.

In FY 2024 , Jagsonpal Pharmaceuticals Ltd recorded a total revenue of approximately 268.72 Cr marking a significant milestone in the company's financial performance.

Jagsonpal Pharmaceuticals Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.3% and 0.1% annually, respectively..

Jagsonpal Pharmaceuticals Ltd's current PE ratio is 25.90.

Jagsonpal Pharmaceuticals Ltd's ROCE averaged 19.1% from the FY ending March 2023 to 2025, with a median of 20.4%. It peaked at 21.4% in March 2023, reflecting strong capital efficiency over the period..

Jagsonpal Pharmaceuticals Ltd's latest EBIT is Rs. 70.82 Cr, surpassing the average EBIT of Rs. 45.57 Cr over the 5 years..